| Literature DB >> 32579667 |
Christopher A Moxon1,2,3, Yasir Alhamdi2, Janet Storm4, Julien M H Toh5, Dagmara McGuinness1, Joo Yeon Ko6, George Murphy7, Steven Lane8, Terrie E Taylor9,10, Karl B Seydel9,10, Sam Kampondeni11, Michael Potchen12, James S O'Donnell13, Niamh O'Regan13, Guozheng Wang2, Guillermo García-Cardeña14, Malcolm Molyneux3,4, Alister G Craig4, Simon T Abrams2, Cheng-Hock Toh2,15.
Abstract
Microvascular thrombosis and blood-brain barrier (BBB) breakdown are key components of cerebral malaria (CM) pathogenesis in African children and are implicated in fatal brain swelling. How Plasmodium falciparum infection causes this endothelial disruption and why this occurs, particularly in the brain, is not fully understood. In this study, we have demonstrated that circulating extracellular histones, equally of host and parasite origin, are significantly elevated in CM patients. Higher histone levels are associated with brain swelling on magnetic resonance imaging. On postmortem brain sections of CM patients, we found that histones are colocalized with P falciparum-infected erythrocytes sequestered inside small blood vessels, suggesting that histones might be expelled locally during parasite schizont rupture. Histone staining on the luminal vascular surface colocalized with thrombosis and leakage, indicating a possible link between endothelial surface accumulation of histones and coagulation activation and BBB breakdown. Supporting this, patient sera or purified P falciparum histones caused disruption of barrier function and were toxic to cultured human brain endothelial cells, which were abrogated with antihistone antibody and nonanticoagulant heparin. Overall, our data support a role for histones of parasite and host origin in thrombosis, BBB breakdown, and brain swelling in CM, processes implicated in the causal pathway to death. Neutralizing histones with agents such as nonanticoagulant heparin warrant exploration to prevent brain swelling in the development or progression of CM and thereby to improve outcomes.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32579667 PMCID: PMC7362376 DOI: 10.1182/bloodadvances.2019001258
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529